Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
From BioCentury This Week · · 32 min
This plays from the publisher's own server. We do not host a copy.
Description
Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it (https://www.biocentury.com/article/660381). The team also discusses what lessons can be learned from the regulatory roller-coaster ride (https://www.biocentury.com/article/660358) of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point (https://www.biocentury.com/article/660346) in treating depression.
View full story: https://www.biocentury.com/article/660376
#BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus
00:00 - Introduction 00:51 - AZ-BMS Rumors 08:07 - Replimune 20:46 - Psychedelics
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)